Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06573424Completed

Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC

Role: lead

NCT06718543Phase 2Recruiting

Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer

Role: lead

NCT05985239Completed

Virtual Ileostomy Versus Diverting Ileostomy

Role: lead

NCT06225609Not ApplicableNot Yet Recruiting

No Stoma VS Ghost Stoma in Patients Undergoing Total Mesorectal Excision for Rectal Cancer

Role: lead

NCT05833672Phase 2Unknown

Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers

Role: lead

NCT05482529Unknown

Integrative Omics Analysis for Colorectal Cancer and Metastasis

Role: lead

All 6 trials loaded